1. Home
  2. CYTK vs LFUS Comparison

CYTK vs LFUS Comparison

Compare CYTK & LFUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$69.87

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Logo Littelfuse Inc.

LFUS

Littelfuse Inc.

N/A

Current Price

$402.96

Market Cap

11.7B

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
LFUS
Founded
1997
1927
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Electrical Products
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.7B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
CYTK
LFUS
Price
$69.87
$402.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
3
Target Price
$89.26
$366.67
AVG Volume (30 Days)
1.7M
181.2K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
0.77%
EPS Growth
N/A
N/A
EPS
N/A
2.96
Revenue
$13,368,000.00
$757,853,000.00
Revenue This Year
$7.37
$14.65
Revenue Next Year
$310.19
$6.98
P/E Ratio
N/A
$133.67
Revenue Growth
N/A
N/A
52 Week Low
$47.22
$233.36
52 Week High
$88.31
$500.57

Technical Indicators

Market Signals
Indicator
CYTK
LFUS
Relative Strength Index (RSI) 35.17 39.98
Support Level $59.10 $388.95
Resistance Level $70.69 $426.44
Average True Range (ATR) 2.61 13.05
MACD -0.19 -1.10
Stochastic Oscillator 6.71 6.55

Price Performance

Historical Comparison
CYTK
LFUS

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About LFUS Littelfuse Inc.

Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.

Share on Social Networks: